Compare Moderna, Inc. (MRNA) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nucor Corporation — how do they compare? Moderna, Inc. trades at $136.8 (market cap $54.14B), while Nucor Corporation trades at $257.93 (market cap $58.51B). The key difference: Moderna, Inc. and Nucor Corporation are close in size by market cap, and Nucor Corporation pays a 0.87% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NUE | |
|---|---|---|
Market Cap | $54.14B | $58.51B |
Sector | Health | Basic Materials |
52-Week High | $174.38 | $274.74 |
52-Week Low | $22.36 | $131.78 |
Enterprise Value | $50.29B | $62.92B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Nucor (NUE) trades at $256.4, down 1.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the stock benefits from positive sentiment around U.S. steel demand and tariff protections. The company maintains solid profitability with a net margin of 7.99% and ROE of 13.52%, though revenue has moderated from 2022 peaks.
Outlook is positive with a consensus price target of $281.38, implying ~10% upside. Key opportunities include infrastructure demand and new capacity, while risks involve cyclical steel industry pressures and volatile cash flows. Institutional buying, like CalSTRS' increased stake, supports confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
